Alan White

Alan White explores alternative ways for life sciences firms to keep hold of experienced, qualified professionals as demand for pharmacovigilance skills soars.

AI has huge potential, but the key to ROI is in the application, writes Alan White.

Rife M&A activity the life sciences harms competition and reduces choice, both for patients and for more modest-sized pharma and biotech firms seeking help with growing pharmacovigilance and regulatory filing requirements, writes Alan White.